Trastuzumab Deruxtecan in Previously Treated HER2-Low

Trastuzumab Deruxtecan in Previously Treated HER2-Low trastuzumab On April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, trastuzumab Descriptions Trastuzumab injection is used to treat HER2-overexpressing new or metastatic breast cancer It can be

trastuzumab Possible Side Effects of Trastuzumab · Heart Problems · Infusion-Related Side Effects · Lung Problems · Low White Blood Cell Count (Leukopenia

trastuzumab Subcutaneous trastuzumab has a similar safety profile to intravenous trastuzumab and is non-inferior in terms of pharmacokinetic profile and efficacy and Self-Care Tips: · Drink at least two to three quarts of fluid every 24 hours, unless you are instructed otherwise · Trastuzumab causes little nausea · You may